Keyword: Imfinzi (durvalumab)
Kyowa is also testing the drug in early-phase trials for solid tumors, in combo with its own IDO inhibitor KHK2455, BMS’ Opdivo and AZ’s Imfinzi.
AstraZeneca's CEO knows he keeps saying the same thing, but once again, he had just one message for investors Thursday: Hang in there.
Imfinzi already is I-O's only FDA-approved maintenance therapy in lung cancer. Friday, the AZ med hit another benchmark to stretch out that lead.
Crestor sales nosedived by 42% to $389 million in Q1, well below analyst estimates, but execs hope new cancer drugs can cushion the fall.
AstraZeneca slashed CEO Pascal Soriot’s total pay by 34% in 2017, but that cut wasn’t deep enough for one influential voice on corporate governance.
AstraZeneca has come up short in another lung cancer trial of its immuno-oncology combo.
BioMarin knows winning drug names. For the second time, one of its drugs won our #FierceMadness tournament—thanks in large part to BioMarin employees.
First rule of ballot stuffing? To avoid raising red flags, don't overdo it. And that’s exactly what 34,035 #FierceMadness votes for Brineura did.
The final showdown is set: BioMarin’s Brineura will face off against AstraZeneca’s Imfinzi in the drug name championship for 2018.
Under a 2003 agreement, Array BioPharma says AstraZeneca needs to pony up $192 million.